Alphamab Oncology (HKSE:09966) 3-Year EBITDA Growth Rate : 33.10% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology 3-Year EBITDA Growth Rate?

Alphamab Oncology's EBITDA per Share for the six months ended in Dec. 2023 was HK$-0.15.

During the past 3 years, the average EBITDA Per Share Growth Rate was 33.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alphamab Oncology was 43.50% per year. The lowest was -79.50% per year. And the median was 4.55% per year.

Competitive Comparison of Alphamab Oncology's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Alphamab Oncology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's 3-Year EBITDA Growth Rate falls into.

Alphamab Oncology 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Alphamab Oncology (HKSE:09966) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alphamab Oncology 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines